Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 1
Submit an article Journal homepage
9,969
Views
2
CrossRef citations to date
0
Altmetric
Coronavirus – Commentary

SARS-CoV-2 vaccination in the context of original antigenic sin

Marek Petráša Department of Epidemiology and Biostatistics, Charles University Third Faculty of Medicine, Prague, Czech RepublicCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2913-1736
ORCID Icon &
Ivana Králová Lesnáb Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;c Department of Anesthesia and Intensive Medicine, First Faculty of Medicine, Charles University and University Military Hospital, Prague, Czech RepublicORCID Iconhttps://orcid.org/0000-0002-9053-4123
ORCID Icon
Article: 1949953 | Received 12 May 2021, Accepted 22 Jun 2021, Published online: 09 Jul 2021

References

  • JANSSEN BIOTECH, INC. COVID-19 vaccine Ad26.COV2.S VAC31518 (JNJ-78436735). Vaccines and related biological products advisory committee meeting; Meeting date: 2021 February 26. [accessed 2021 March 15]. https://www.fda.gov/media/146219/download .
  • AstraZeneca. COVID-19 vaccine AstraZeneca. Assessment report. Common name: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Procedure No. EMEA/H/C/005675/0000; [accessed 2021 March 15]. https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf .
  • Francis T, Davenport FM, Hennessy AV. A serological recapitulation of human infection with different strains of influenza virus. Trans Assoc Am Physicians. 1953;66:231–3.
  • Vatti A, Monsalve DM, Pacheco Y, Chang C, Anaya JM, Gershwin ME. Original antigenic sin: a comprehensive review. J Autoimmun. 2017;83:12–21. doi:10.1016/j.jaut.2017.04.008.
  • Centers for Disease Control and Prevention (CDC). Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009; 58:521–24.
  • Jacob J, Kelsoe G, Rajewsky K, Weiss U. Intraclonal generation of antibody mutants in germinal centres. Nature. 1991;354:389–92. doi:10.1038/354389a0.
  • Wisseman CL, Sweet BH, Kitaoka M, Tamiya T. Immunological studies with group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus. Am J Trop Med Hyg. 1962;11:550–61. doi:10.4269/ajtmh.1962.11.550.
  • Masurel N, Ophof P, de Jong P. Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus. J Hyg (Lond). 1981;87:201–09. doi:10.1017/s0022172400069412.
  • Chakradhar S. Updated, augmented vaccines compete with original antigenic sin. Nat Med. 2015;21:540–41. doi:10.1038/nm0615-540.
  • Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, Di Giovanni P, Sticchi L, Gentile C, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One. 2009;4:e4384. doi:10.1371/journal.pone.0004384.
  • Park MS, Kim JI, Park S, Lee I, Park MS. Original antigenic sin response to RNA viruses and antiviral immunity. Immune Netw. 2016;16:261–70. doi:10.4110/in.2016.16.5.261.
  • Holzmann H, Kundi M, Stiasny K, Clement J, McKenna P, Kunz C, Heinz FX. Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis. J Med Virol. 1996;48:102–07. doi:10.1002/(sici)1096-9071(199601)48:1<102::Aid-jmv16>3.0.Co;2-i.
  • Filipe AR, Martins CM, Rocha H. Laboratory infection with Zika virus after vaccination against yellow fever. Arch Gesamte Virusforsch. 1973;43:315–19. doi:10.1007/bf01556147.
  • Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384:80–82. doi:10.1056/NEJMc2032195.
  • Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature. 2020;586:594–99. doi:10.1038/s41586-020-2814-7.
  • Samanovic MI, Cornelius AR, Wilson JP, Karmacharya T, Gray-Gaillard SL, Allen JR, Hyman SW, Moritz G, Ali M, Koralov SB, et al. Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals. medRxiv [Preprint]. 2021 Feb 9. doi:10.1101/2021.02.07.21251311. PMID: 33594383; PMCID: PMC7885942.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.